Therapies for osteoarthritis today and tomorrow: Review

Osteoarthritis is a common human disease with well understood pathophysiology, signs and symptoms, prevalence, risk factors, pain, and suffering with great understanding of personal, economic and social effects around the world. There are no drugs or treatments considered "disease modifying&quo...

Full description

Bibliographic Details
Main Author: Skrepnik Nebojša
Format: Article
Language:English
Published: Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine 2020-01-01
Series:Scripta Medica
Subjects:
Online Access:https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2020/2490-33292003181S.pdf
id doaj-2eb0d78d8ee848acacefaa3d3d1f056a
record_format Article
spelling doaj-2eb0d78d8ee848acacefaa3d3d1f056a2020-11-25T04:00:25ZengMedical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of MedicineScripta Medica2490-33292303-79542020-01-015131811892490-33292003181STherapies for osteoarthritis today and tomorrow: ReviewSkrepnik Nebojša0Tucson Orthopaedic Institute, Research Center, Tucson, Arizona, USAOsteoarthritis is a common human disease with well understood pathophysiology, signs and symptoms, prevalence, risk factors, pain, and suffering with great understanding of personal, economic and social effects around the world. There are no drugs or treatments considered "disease modifying", with symptomatic control aiming to stave off the final solution of total joint replacement. Regenerative medicine and use of mesenchymal stem cells (MSC) promised hope to change that but have so far fallen short. This review focuses on current knowledge and use of MSC in clinic, completed research, and future directions for development of this once so promising biological treatment. Powerful treatment for pain in form of monoclonal antibodies against Nerve Growth Factor (NGF) are getting close to FDA approval in the US. Wnt signaling pathway modulators that decrease inflammation, increase function and potential to regenerate cartilage should be presented to the FDA early next year.https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2020/2490-33292003181S.pdfosteoarthritismesenchymal stem cellswnt pathwayngf antibodies
collection DOAJ
language English
format Article
sources DOAJ
author Skrepnik Nebojša
spellingShingle Skrepnik Nebojša
Therapies for osteoarthritis today and tomorrow: Review
Scripta Medica
osteoarthritis
mesenchymal stem cells
wnt pathway
ngf antibodies
author_facet Skrepnik Nebojša
author_sort Skrepnik Nebojša
title Therapies for osteoarthritis today and tomorrow: Review
title_short Therapies for osteoarthritis today and tomorrow: Review
title_full Therapies for osteoarthritis today and tomorrow: Review
title_fullStr Therapies for osteoarthritis today and tomorrow: Review
title_full_unstemmed Therapies for osteoarthritis today and tomorrow: Review
title_sort therapies for osteoarthritis today and tomorrow: review
publisher Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine
series Scripta Medica
issn 2490-3329
2303-7954
publishDate 2020-01-01
description Osteoarthritis is a common human disease with well understood pathophysiology, signs and symptoms, prevalence, risk factors, pain, and suffering with great understanding of personal, economic and social effects around the world. There are no drugs or treatments considered "disease modifying", with symptomatic control aiming to stave off the final solution of total joint replacement. Regenerative medicine and use of mesenchymal stem cells (MSC) promised hope to change that but have so far fallen short. This review focuses on current knowledge and use of MSC in clinic, completed research, and future directions for development of this once so promising biological treatment. Powerful treatment for pain in form of monoclonal antibodies against Nerve Growth Factor (NGF) are getting close to FDA approval in the US. Wnt signaling pathway modulators that decrease inflammation, increase function and potential to regenerate cartilage should be presented to the FDA early next year.
topic osteoarthritis
mesenchymal stem cells
wnt pathway
ngf antibodies
url https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2020/2490-33292003181S.pdf
work_keys_str_mv AT skrepniknebojsa therapiesforosteoarthritistodayandtomorrowreview
_version_ 1724450736776937472